Champions Oncology to Announce First Quarter Financial Results on Monday, September 15, 2025
Champions Oncology (NASDAQ:CSBR), a global preclinical and clinical research services provider specializing in oncology solutions, has scheduled its first quarter fiscal 2025 financial results announcement for Monday, September 15, 2025, after market close.
The company will host a conference call at 4:30 P.M. EDT to discuss the results. Investors can join via phone using access code 261008 or listen to the replay within 72 hours through the company's website or by phone using passcode 52943.
Champions Oncology (NASDAQ:CSBR), fornitore globale di servizi di ricerca preclinica e clinica specializzato in soluzioni oncologiche, ha programmato la pubblicazione dei risultati finanziari del primo trimestre fiscale 2025 per lunedì 15 settembre 2025, dopo la chiusura del mercato.
La società terrà una conference call alle 16:30 EDT per commentare i risultati. Gli investitori possono partecipare telefonicamente usando il codice di accesso 261008 oppure ascoltare la registrazione entro 72 ore tramite il sito web della società o telefonicamente usando il passcode 52943.
Champions Oncology (NASDAQ:CSBR), proveedor global de servicios de investigación preclínica y clínica especializado en soluciones oncológicas, ha programado el anuncio de sus resultados financieros del primer trimestre fiscal 2025 para el lunes 15 de septiembre de 2025, tras el cierre del mercado.
La compañía celebrará una conferencia telefónica a las 16:30 EDT para comentar los resultados. Los inversores pueden unirse por teléfono con el código de acceso 261008 o escuchar la grabación durante 72 horas a través del sitio web de la compañía o por teléfono con el passcode 52943.
Champions Oncology (NASDAQ:CSBR)는 종양학 솔루션을 전문으로 하는 글로벌 전임상 및 임상 연구 서비스 제공업체로서, 2025년 9월 15일 월요일 회계연도 2025 회계연도 1분기 재무실적 발표를 장 마감 후로 예정했습니다.
회사는 결과를 논의하기 위해 동부 일광절약시간(EDT) 기준 오후 4시 30분에 컨퍼런스 콜을 진행합니다. 투자자는 접속 코드 261008을 사용해 전화로 참여할 수 있으며, 회사 웹사이트를 통해 또는 전화로 패스코드 52943을 사용해 발표 후 72시간 이내에 재청취할 수 있습니다.
Champions Oncology (NASDAQ:CSBR), prestataire mondial de services de recherche préclinique et clinique spécialisé dans les solutions oncologiques, a programmé la publication de ses résultats financiers du premier trimestre fiscal 2025 pour le lundi 15 septembre 2025, après la clôture des marchés.
La société tiendra une conférence téléphonique à 16h30 HAE pour commenter les résultats. Les investisseurs peuvent participer par téléphone en utilisant le code d'accès 261008 ou écouter la rediffusion pendant 72 heures via le site web de la société ou par téléphone avec le passcode 52943.
Champions Oncology (NASDAQ:CSBR), ein globaler Anbieter von vorklinischen und klinischen Forschungsdienstleistungen mit Schwerpunkt auf onkologischen Lösungen, hat die Bekanntgabe der Finanzergebnisse für das erste Quartal des Geschäftsjahres 2025 für Montag, den 15. September 2025 nach Börsenschluss terminiert.
Das Unternehmen wird um 16:30 Uhr EDT eine Telefonkonferenz abhalten, um die Ergebnisse zu besprechen. Investoren können per Telefon mit dem Zugangs-Code 261008 teilnehmen oder die Aufzeichnung innerhalb von 72 Stunden über die Website des Unternehmens oder telefonisch mit dem Passcode 52943 anhören.
- None.
- None.
HACKENSACK, NJ / ACCESS Newswire / September 10, 2025 / Champions Oncology, Inc. (Nasdaq:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the quarter ended July 31, 2025, on Monday, September 15, 2025, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EDT (1:30 P.M. PDT). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 261008. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 52943, or by accessing the investors section of the company's website within 72 hours.
About Champions Oncology, Inc.
Champions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions to biopharma organizations. With the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, Champions delivers innovative highest-quality data through proprietary in vivo and ex vivo platforms. Through its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical and clinical oncology drug discovery and development programs worldwide. For more information, please visit www.ChampionsOncology.com.
Media Inquiries:
Gavin Cooper
Vice President, Global Marketing
gcooper@championsoncology.com
Website: https://www.championsoncology.com/
Facebook: https://www.facebook.com/championsoncology/
LinkedIn: https://www.linkedin.com/company/champions-oncology-inc-/
Twitter: @ChampionsOncol1
Instagram: https://www.instagram.com/championsoncology/
SOURCE: Champions Oncology, Inc.
View the original press release on ACCESS Newswire
FAQ
When will Champions Oncology (CSBR) release Q1 2025 earnings?
What time is the Champions Oncology (CSBR) Q1 2025 earnings call?
How can I access Champions Oncology's Q1 2025 earnings call?
Where can I find the replay of Champions Oncology's Q1 2025 earnings call?
